Elitek or Fasturtec Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing chemotherapy usage, historical tls complication rates, early rasburicase approvals, hospital oncology expansion, growing cancer incidence.

The growth in the forecast period can be attributed to rising global cancer burden, expansion of pediatric oncology programs, improved early tls risk assessment, growth in specialty oncology centers, advancements in supportive cancer care. Major trends in the forecast period include rising focus on oncology supportive care, increased use in tumor lysis syndrome, growth in hospital based infusion therapies, expansion of pediatric oncology treatments, improved chemotherapy safety protocols.

The rising prevalence of leukemia is expected to drive growth in the Elitek (Fasturtec) market. Leukemia is caused by the uncontrolled proliferation of abnormal white blood cells in the bone marrow, often triggered by genetic mutations, environmental factors, or exposure to radiation and certain chemicals. Cases of leukemia are increasing due to factors such as aging populations, genetic predispositions, environmental exposures, and improved diagnostics. Elitek (Fasturtec) helps manage high uric acid levels in leukemia patients caused by tumor lysis syndrome (TLS), a condition that occurs when cancer treatments rapidly destroy leukemia cells, releasing large amounts of uric acid into the bloodstream. For example, in 2024, the American Cancer Society, a US-based non-profit cancer organization, reported 62,770 leukemia cases, up from 59,610 in 2023. Consequently, the rising prevalence of leukemia is expected to propel the Elitek (Fasturtec) market.

The increase in healthcare expenditures is also expected to support growth in the Elitek (Fasturtec) market. Healthcare expenditures include all costs related to medical services, family planning, nutrition programs, and emergency health assistance. Rising healthcare costs are primarily driven by the growing prevalence of chronic diseases, which increase demand for continuous treatments, long-term medications, and frequent medical visits. Higher healthcare spending benefits Elitek/Fasturtec as greater investment in oncology care and supportive treatments improves access to advanced therapies for managing TLS, boosting demand for rasburicase in high-risk cancer patients. For example, in May 2025, Statistics Netherlands, the Netherlands’ national statistical office, reported that the country spent approximately $130.7 billion on healthcare in 2024, an increase of $9.79 billion (8.1%) compared to 2023. Therefore, rising healthcare expenditures are expected to drive the Elitek (Fasturtec) market.

A notable trend in the Elitek (Fasturtec) market is the growing focus on adult applications, particularly for managing TLS in cancer patients. With TLS increasingly observed in adults undergoing chemotherapy for aggressive malignancies such as leukemia, lymphoma, and solid tumors, there is rising demand for effective therapies. Companies are expanding the use of their products beyond pediatric indications to address a broader range of cancer treatments. For instance, in October 2023, Sanofi S.A., a France-based pharmaceutical company, received FDA approval for Elitek to manage plasma uric acid levels in adult patients with leukemia, lymphoma, and solid tumors receiving anti-cancer therapy that may lead to TLS. This approval was supported by Phase 3 trial results showing that Elitek significantly reduced plasma uric acid levels compared to standard oral allopurinol therapy, offering a critical option for this potentially life-threatening condition.

Major companies operating in the elitek or fasturtec market are Sanofi S.A.

North America was the largest region in the elitek or fasturtec market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the elitek or fasturtec market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the elitek or fasturtec market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the elitek or fasturtec market by increasing costs of active enzymes, sterile injectables, and pharmaceutical logistics. These impacts are most significant in hospital pharmacy and oncology clinic segments, especially in regions reliant on imported oncology drugs. Higher tariffs can strain hospital procurement budgets and affect treatment accessibility. At the same time, tariffs are supporting localized pharmaceutical manufacturing, strengthening regional oncology supply chains, and encouraging long term cost optimization strategies.

The elitek or fasturtec market research report is one of a series of new reports that provides elitek or fasturtec market statistics, including elitek or fasturtec industry global market size, regional shares, competitors with a elitek or fasturtec market share, detailed elitek or fasturtec market segments, market trends and opportunities, and any further data you may need to thrive in the elitek or fasturtec industry. This elitek or fasturtec market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Elitek (known as Fasturtec outside the US) is a medication containing rasburicase, used to treat or prevent elevated uric acid levels caused by tumor lysis syndrome (TLS) in cancer patients undergoing chemotherapy. It works by converting uric acid into allantoin, which is more easily excreted by the kidneys, thereby reducing the risk of kidney damage. It is administered intravenously and is particularly important for patients with leukemia, lymphoma, or other malignancies that rapidly release uric acid during treatment.

The primary dosage forms in the elitek or fasturtec market are injectable and lyophilized powder. Injectable rasburicase is a prescription medication used to manage hyperuricemia resulting from cancer treatments in patients with leukemia, lymphoma, or other malignancies. Its clinical indications include tumor lysis syndrome (TLS) and related conditions. The patient population includes both pediatric and adult patients, with distribution through hospital pharmacies, retail pharmacies, and online pharmacies. End users comprise hospitals, clinics, ambulatory care centers, and home care settings.

The elitek or fasturtec market consists of sales of supportive medications and combination therapy kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.